Search

Coronavirus Disease-2019 (COVID-19) can be classified as a respiratory disease that ranges from pneumonia to critically ill cases. Extracorporeal Membrane Oxygenation (ECMO) is a therapeutic procedure that can treat severe cases of respiratory failure. Hereby, the authors present, a 28-year-old case of Acute Respiratory Distress Syndrome (ARDS) young patient with COVID-19 on ECMO therapy, presenting with complaints of weakness, decreased mobility and function, and depression. The patient has received physical therapy interventions during the hospitalisation period. Respiratory, mobility, activity level, and psychological assessments were done before and after treatment using blood gases, the Intensive Care Unit (ICU) Mobility Scale, the University of Michigan scale, and the Hamilton Anxiety and Depression Rating Scale, respectively. There was an improvement in respiratory function, mobility (scores increased from 0 to 1), activity level (scores increased from 0 to 3), and psychological well-being (depression scores decreased from 18 to 15, and anxiety scores decreased from 20 to 14) after physical therapy. The treatment resulted in better recovery and prevented the worsening of the COVID-19 disease scenario.

Introduction: Large Tumour Suppressor (LATS) family proteins were discovered for the first time in Drosophila in 1995. Since that date, LATS proteins have been considered tumour suppressors. The family includes two members, LATS1 and LATS2, which have a chief function in the control of tumour growth and cell cycles through several mechanisms and signalling pathways, including those of p53, Hippo, and Wnt. LATS2 gene was involved in many types of haematological malignancies as it plays a role in the leukaemogenesis of AML and also in the clinical outcome of the disease. Aim: The current study was an attempt to clarify the relation of LATS2 gene expression and clinical manifestations of Acute Myeloid Leukaemia (AML). Materials and Methods: The present case-control study included 60 adult denovo AML patients and 60 age and sex matched healthy controls for analysis of LATS2 mRNA gene expression level by Real Time-Quantitative Polymerase Chain Reaction (RT-QPCR) technique. Data were analysed using IBM SPSS advanced statistics version 22.0 (SPSS Inc., Chicago, IL). Results: The expression level of LATS2 gene was significantly higher in AML patients compared to controls (p